Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Targeted therapies for gastroesophageal adenocarcinoma

Daniel Catenacci, MD, University of Chicago, Chicago, IL, talks on the targeted therapy treatment landscape for patients with gastroesophageal adenocarcinoma including the use of HER2-targeting agents, as well as the development of molecular biomarkers of response to immune checkpoint blockade. In addition, Dr Catenacci highlights claudin as a valuable biomarker, and the use of zolbetuximab, a monoclonal antibody targeting claudin which has shown efficacy in metastatic gastric or gastroesophageal junction adenocarcinoma and is currently being evaluated in two Phase III trials, SPOTLIGHT (NCT03504397) and GLOW (NCT03653507). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Daniel Catenacci, MD has received support/funding from Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Tempus, Guardant Health, Archer & Natera.